Y-mAbs Therapeutics, Inc.
General ticker "YMAB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $435.4M (TTM average)
Y-mAbs Therapeutics, Inc. follows the US Stock Market performance with the rate: 8.1%.
Estimated limits based on current volatility of 4.0%: low 3.91$, high 4.23$
Factors to consider:
- Earnings expected soon, date: 2025-05-13 bmo
- US accounted for 75.2% of revenue in the fiscal year ended 2024-12-31
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.24$, 11.59$]
- 2025-12-31 to 2026-12-31 estimated range: [2.89$, 8.28$]
Financial Metrics affecting the YMAB estimates:
- Negative: Non-GAAP EPS, $ of -0.67 <= 0.04
- Negative: Operating cash flow per share per price, % of -3.47 <= 1.79
- Negative: negative Operating income
- Positive: Shareholder equity ratio, % of 76.73 > 63.75
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term YMAB quotes
Long-term YMAB plot with estimates
Financial data
YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
---|---|---|---|
Operating Revenue | $65.27MM | $84.82MM | $87.69MM |
Operating Expenses | $160.08MM | $110.49MM | $118.89MM |
Operating Income | $-94.81MM | $-25.67MM | $-31.20MM |
Non-Operating Income | $-0.76MM | $4.81MM | $1.39MM |
R&D Expense | $91.57MM | $54.22MM | $48.99MM |
Income(Loss) | $-95.57MM | $-20.87MM | $-29.81MM |
Taxes | $0.00MM | $0.56MM | $-0.15MM |
Profit(Loss)* | $-96.33MM | $-21.43MM | $-29.67MM |
Stockholders Equity | $109.22MM | $100.98MM | $92.00MM |
Inventory | $6.70MM | $5.07MM | $7.21MM |
Assets | $141.46MM | $127.87MM | $119.90MM |
Operating Cash Flow | $-75.92MM | $-27.23MM | $-15.71MM |
Investing Cash Flow | $0.04MM | $0.01MM | $0.00MM |
Financing Cash Flow | $0.08MM | $0.10MM | $4.31MM |
Earnings Per Share** | $-2.20 | $-0.49 | $-0.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.